Media coverage about Novogen Limited (NASDAQ:NVGN) has been trending positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novogen Limited earned a media sentiment score of 0.35 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.7240153159512 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several brokerages have weighed in on NVGN. ValuEngine lowered shares of Novogen Limited from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Zacks Investment Research lowered shares of Novogen Limited from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd.

Shares of Novogen Limited (NVGN) traded up 1.26% on Friday, reaching $3.22. 1,806 shares of the company’s stock traded hands. The company has a 50 day moving average price of $2.86 and a 200 day moving average price of $1.60. Novogen Limited has a 52 week low of $0.70 and a 52 week high of $3.82. The firm’s market capitalization is $15.56 million.

COPYRIGHT VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2017/08/27/positive-press-coverage-somewhat-unlikely-to-affect-novogen-limited-nvgn-stock-price.html.

About Novogen Limited

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.

Insider Buying and Selling by Quarter for Novogen Limited (NASDAQ:NVGN)

Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.